Evidence map›Paper›PMID 19390518›Full record

Trial reportObesity (Silver Spring, Md.)2009

Changes in health state utilities with changes in body mass in the Diabetes Prevention Program.

Ronald T Ackermann, Sharon L Edelstein, K M Venkat Narayan, Ping Zhang, Michael M Engelgau, William H Herman, David G Marrero, Diabetes Prevention Program Research Group

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Obesity (Silver Spring, Md.), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07240246 (Effect of a Dietary Supplement), which is not on this map. Cited by 45 papers, 5 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 5 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07240246 nacompletednot on this mapstarted 2025, after this paper: background citation

Effect of a Dietary Supplement (FitLine TopShape) on the Incretin Response

TypeinterventionalSponsorFFoQSI - Austrian Competence Centre for Feed and Food Quality, Safety & InnovationRan2025 to 2026Enrolled40ConditionsGLP-1, Obesity &Amp, Overweight, Dietary SupplementArmsIntervention: Dietary Supplement with Plant Extracts, Placebo
3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 5 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Trial
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Predictors of health-related quality of life changes after lifestyle intervention in persons at risk of type 2 diabetes mellitus.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2014
    Trial
  14. Trial
  15. Trial
  16. Patient-reported outcomes in the practice-based opportunities for weight reduction (POWER) trial.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2013
    Trial
  17. Trial
  18. The effect of weight loss on changes in health-related quality of life among overweight and obese women with urinary incontinence.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2012
    Trial
  19. Trial
  20. Trial
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Ronald T AckermannDepartment of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. dppmail@biostat.bsc.gwu.edu
Sharon L Edelstein
K M Venkat Narayan
Ping Zhang
Michael M Engelgau
William H Herman
David G Marrero
Diabetes Prevention Program Research Group

Funding

PRIMARY PREVENTION TRIAL--DATA COORDINATING CENTERU01DK048489 · NIDDK · GEORGE WASHINGTON UNIVERSITY · PI JABLONSKI, KATHLEEN ANN, TEMPROSA, MARINELLA · 1994 to 2021
$84.8M
Intramural NIH HHSNIDDK NIH HHS U01 DK048489
6 · The paper itself

Abstract

Health utilities are measures of health-related quality of life (HRQL) used in cost-effectiveness research. We evaluated whether changes in body weight were associated with changes in health utilities in the Diabetes Prevention Program (DPP) and whether associations differed by treatment assignment (lifestyle intervention, metformin, placebo) or baseline obesity severity. We constructed physical (PCS-36) and mental component summary (MCS-36) subscales and short-form-6D (SF-6D) health utility index for all DPP participants completing a baseline 36-item short form (SF-36) HRQL assessment (N = 3,064). We used linear regression to test associations between changes in body weight and changes in HRQL indicators, while adjusting for other demographic and behavioral variables. Overall differences in HRQL between treatment groups were highly statistically significant but clinically small after 1 year. In multivariable models, weight change was independently associated with change in SF-6D score (increase of 0.007 for every 5 kg weight loss; P < 0.001), but treatment effects independent of weight loss were not. We found no significant interaction between baseline obesity severity and changes in SF-6D with changes in body weight. However, increases in physical function (PCS-36) with weight loss were greater in persons with higher baseline obesity severity. In summary, improvements in HRQL are associated with weight loss but not with other effects of obesity treatments that are unrelated to weight loss. Although improvements in the SF-6D did not exceed commonly reported thresholds for a minimally important difference (0.04), these changes, if causal, could still have a significant impact on clinical cost-effectiveness estimates if sustained over multiple years.

Indexed as

Diet, ReducingExerciseQuality of LifeWeight LossActivities of Daily LivingAdultCost-Benefit AnalysisDiabetes MellitusFemaleHumansHypoglycemic AgentsLife StyleLinear ModelsMaleMetforminMiddle AgedHypoglycemic AgentsMetformin

Identifiers

PMID19390518
PMCPMC3135001

What OpenQuestion holds

Texttitle and abstract
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.